247 related articles for article (PubMed ID: 14570767)
21. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19.
Wienkers LC; Wurden CJ; Storch E; Kunze KL; Rettie AE; Trager WF
Drug Metab Dispos; 1996 May; 24(5):610-4. PubMed ID: 8723744
[TBL] [Abstract][Full Text] [Related]
22. Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro.
Polasek TM; Elliot DJ; Lewis BC; Miners JO
J Pharmacol Exp Ther; 2004 Dec; 311(3):996-1007. PubMed ID: 15304522
[TBL] [Abstract][Full Text] [Related]
23. The inhibitory effect of tannic acid on cytochrome P450 enzymes and NADPH-CYP reductase in rat and human liver microsomes.
Yao HT; Chang YW; Lan SJ; Yeh TK
Food Chem Toxicol; 2008 Feb; 46(2):645-53. PubMed ID: 17950511
[TBL] [Abstract][Full Text] [Related]
24. Characterization of inhibitory effects of perfluorooctane sulfonate on human hepatic cytochrome P450 isoenzymes: focusing on CYP2A6.
Narimatsu S; Nakanishi R; Hanioka N; Saito K; Kataoka H
Chem Biol Interact; 2011 Nov; 194(2-3):120-6. PubMed ID: 21964418
[TBL] [Abstract][Full Text] [Related]
25. Inhibition of cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases by vicagrel in human liver microsomes: A prediction of potential drug-drug interactions.
Liu S; Wang Z; Chan E; Zhao Y; Kang J; Zhang X; Tian X
Chem Biol Interact; 2022 Jan; 352():109775. PubMed ID: 34910929
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes.
McGinnity DF; Berry AJ; Kenny JR; Grime K; Riley RJ
Drug Metab Dispos; 2006 Aug; 34(8):1291-300. PubMed ID: 16679385
[TBL] [Abstract][Full Text] [Related]
27. Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes.
Yoshii K; Kobayashi K; Tsumuji M; Tani M; Shimada N; Chiba K
Life Sci; 2000; 67(2):175-84. PubMed ID: 10901285
[TBL] [Abstract][Full Text] [Related]
28. A predominate role of CYP1A2 for the metabolism of nabumetone to the active metabolite, 6-methoxy-2-naphthylacetic acid, in human liver microsomes.
Turpeinen M; Hofmann U; Klein K; Mürdter T; Schwab M; Zanger UM
Drug Metab Dispos; 2009 May; 37(5):1017-24. PubMed ID: 19204080
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory Effects of Aschantin on Cytochrome P450 and Uridine 5'-diphospho-glucuronosyltransferase Enzyme Activities in Human Liver Microsomes.
Kwon SS; Kim JH; Jeong HU; Cho YY; Oh SR; Lee HS
Molecules; 2016 Apr; 21(5):. PubMed ID: 27128896
[TBL] [Abstract][Full Text] [Related]
30. Identification of human cytochrome P450 isoforms involved in the 3-hydroxylation of quinine by human live microsomes and nine recombinant human cytochromes P450.
Zhao XJ; Yokoyama H; Chiba K; Wanwimolruk S; Ishizaki T
J Pharmacol Exp Ther; 1996 Dec; 279(3):1327-34. PubMed ID: 8968357
[TBL] [Abstract][Full Text] [Related]
31. Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes.
Niwa T; Inoue-Yamamoto S; Shiraga T; Takagi A
Biol Pharm Bull; 2005 Sep; 28(9):1813-6. PubMed ID: 16141569
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline.
Murray S; Odupitan AO; Murray BP; Boobis AR; Edwards RJ
Xenobiotica; 2001 Mar; 31(3):135-51. PubMed ID: 11465391
[TBL] [Abstract][Full Text] [Related]
33. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes.
Bourrié M; Meunier V; Berger Y; Fabre G
J Pharmacol Exp Ther; 1996 Apr; 277(1):321-32. PubMed ID: 8613937
[TBL] [Abstract][Full Text] [Related]
34. Inhibitory effects of azelastine and its metabolites on drug oxidation catalyzed by human cytochrome P-450 enzymes.
Nakajima M; Ohyama K; Nakamura S; Shimada N; Yamazaki H; Yokoi T
Drug Metab Dispos; 1999 Jul; 27(7):792-7. PubMed ID: 10383922
[TBL] [Abstract][Full Text] [Related]
35. Rate-limiting biotransformation of triamterene is mediated by CYP1A2.
Fuhr U; Kober S; Zaigler M; Mutschler E; Spahn-Langguth H
Int J Clin Pharmacol Ther; 2005 Jul; 43(7):327-34. PubMed ID: 16035375
[TBL] [Abstract][Full Text] [Related]
36. The alkaloid rutaecarpine is a selective inhibitor of cytochrome P450 1A in mouse and human liver microsomes.
Ueng YF; Jan WC; Lin LC; Chen TL; Guengerich FP; Chen CF
Drug Metab Dispos; 2002 Mar; 30(3):349-53. PubMed ID: 11854157
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of human drug metabolizing cytochrome P450 by buprenorphine.
Umehara K; Shimokawa Y; Miyamoto G
Biol Pharm Bull; 2002 May; 25(5):682-5. PubMed ID: 12033517
[TBL] [Abstract][Full Text] [Related]
38. Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes.
Masubuchi Y; Horie T
Chem Res Toxicol; 1999 Oct; 12(10):1028-32. PubMed ID: 10525281
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.
Draper AJ; Madan A; Parkinson A
Arch Biochem Biophys; 1997 May; 341(1):47-61. PubMed ID: 9143352
[TBL] [Abstract][Full Text] [Related]
40. Inhibitory effect of glyburide on human cytochrome p450 isoforms in human liver microsomes.
Kim KA; Park JY
Drug Metab Dispos; 2003 Sep; 31(9):1090-2. PubMed ID: 12920163
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]